Presentation is loading. Please wait.

Presentation is loading. Please wait.

Volume 155, Issue 3, Pages (March 1996)

Similar presentations


Presentation on theme: "Volume 155, Issue 3, Pages (March 1996)"— Presentation transcript:

1 Volume 155, Issue 3, Pages 821-826 (March 1996)
Prostate Specific Antigen Detected Prostate Cancer (Clinical Stage T1C): An Interim Analysis  Seth E. Lerner, Thomas M. Seay, Michael L. Blute, Erik J. Bergstralh, David Barrett, Horst Zincke  The Journal of Urology  Volume 155, Issue 3, Pages (March 1996) DOI: /S (01) Copyright © 1996 American Urological Association, Inc. Terms and Conditions

2 Figure 1 Kaplan-Meier progression-free (local/systemic/PSA greater than 0.2 ng./ml.) survival estimate for 257 patients with clinical stage T1c prostate cancer after radical prostatectomy (1987 to 1991) with or without adjuvant treatment. Numbers above lines represent number of patients at risk. The Journal of Urology  , DOI: ( /S (01) ) Copyright © 1996 American Urological Association, Inc. Terms and Conditions

3 Figure 2 Kaplan-Meier progression-free (local/systemic/PSA greater than 0.2 ng./ml.) survival estimates for 257 patients with clinical stage T1c prostate cancer treated with radical prostatectomy with or without adjuvant therapy, according to pathological stage. Numbers above lines represent number of patients at risk. The Journal of Urology  , DOI: ( /S (01) ) Copyright © 1996 American Urological Association, Inc. Terms and Conditions

4 Figure 3 Kaplan-Meier progression-free (local/systemic/PSA greater than 0.2 ng./ml.) survival estimates for 208 patients with clinical stage T1c prostate cancer treated with radical prostatectomy without adjuvant therapy, according to preoperative serum PSA (ng./ml.). Numbers above lines represent number of patients at risk. The Journal of Urology  , DOI: ( /S (01) ) Copyright © 1996 American Urological Association, Inc. Terms and Conditions

5 Figure 4 Kaplan-Meier progression-free (local/systemic/PSA greater than 0.2 ng./ml.) survival estimates for 1,679 patients after radical prostatectomy without adjuvant therapy for stage T2b/c or less prostate cancer according to clinical stage. Numbers above lines represent number of patients at risk. The Journal of Urology  , DOI: ( /S (01) ) Copyright © 1996 American Urological Association, Inc. Terms and Conditions


Download ppt "Volume 155, Issue 3, Pages (March 1996)"

Similar presentations


Ads by Google